More on strong inference
Vincent T DeVita Jr
This article has no abstract so we have provided the first paragraph of the full text.
I want to revisit the subject of my previous editorial—strong inference. It's an important concept. My previous editorial focused on a specific set of clinical studies investigating the treatment of early-stage Hodgkin's disease, but the failure to use strong inference is generic in the design of clinical trials because of the nature of the participants, that is, human subjects. Asking fundamental questions is not easy in clinical trials.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.